Annals of Rehabilitation Medicine

"Hyehoon Choi"

Original Article

Spinal cord injury

Correlation Between Duration From Injury and Bone Mineral Density in Individuals With Spinal Cord Injury: Hyehoon Choi, So-youn Chang, Jaewan Yoo, Seong Hoon Lim, Bo Young Hong, Joon Sung Kim; Ann Rehabil Med 2021;45(1):1-6. Published online February 9, 2021; DOI: https://doi.org/10.5535/arm.20169

Abstract
PDF

Objective
To investigate the correlation between bone mineral density (BMD) and duration of injury in individuals with spinal cord injury (SCI).
Methods
Patients with SCI who visited the outpatient department between January 2009 and January 2019 were enrolled. Patients’ most recent dual energy X-ray absorptiometry images were reviewed. According to the 2007 International Society for Clinical Densitometry guidelines, vertebrae with a local structural change were excluded when deriving spine BMD. If one or no vertebra is suitable for evaluation, spine BMD was judged as “improper for assessment”. Correlation analysis was performed between duration from injury and BMD Z-scores of the hip and spine.
Results
Among 83 individuals with SCI, the spines of 44 were judged as improper for assessment. The correlation analysis showed a significant negative relationship between the duration from injury and femur neck BMD (r=-0.40, p<0.01) and total proximal femur BMD (r=-0.39, p<0.01). However, no significant correlation was found between the duration from injury and spine BMD Z-score.
Conclusion
The duration of SCI correlated with hip BMD, but not with spine BMD. Further, more than half of the individuals with SCI could not undergo spinal assessment due to local structural changes. Therefore, spine BMD measurement is not an appropriate method for predicting future fracture risk in those with SCI.

Citations

Citations to this article as recorded by

Beyond the initial impact: a systematic review of post-traumatic bone loss and its mechanisms
Adibeh Rahmani, Ulrike Weichelt, Denise Jahn, Ellen Otto, Arne Kienzle, Svilen Angelov, Vanessa Hubertus, Jennifer Shue, Alexander P. Hughes, Georg N. Duda, Serafeim Tsitsilonis, Matthias Pumberger, Paul Köhli
Osteoporosis International.2026; 37(1): 15. CrossRef
“I think it was helpful but not as helpful as it could have been” - a qualitative study of the experiences and perspectives of using fitness apps among manual wheelchair users with spinal cord injury
Claire Hickey, Éimear Smith, Sara Hayes
Disability and Rehabilitation.2025; 47(3): 633. CrossRef
High prevalence of low bone mineral density in wheelchair users regardless of sports participation: a cross-sectional analysis of the bonewheel study
Linn C. Risvang, Jan-Willem van Dijk, Julia K. Baumgart, Hannah M. Rice, Anja M. F. Liljegren, Vegard Strøm, Truls Raastad, Kristin L. Jonvik
European Journal of Applied Physiology.2025;[Epub] CrossRef
Bone Mineral Density Post a Spinal Cord Injury: A Review of the Current Literature Guidelines
Georgia Antoniou, Ioannis S Benetos, John Vlamis, Spyros G Pneumaticos
Cureus.2022;[Epub] CrossRef

7,411 View
205 Download
4 Web of Science
4 Crossref

Case Report

Botulinum Toxin Type A Injection for Neuropathic Pain in a Patient With a Brain Tumor: A Case Report: Kyung Eun Nam, Joon Sung Kim, Bo Young Hong, Bomi Sul, Hyehoon Choi, So Yeon Jun, Seong Hoon Lim; Ann Rehabil Med 2017;41(6):1088-1092. Published online December 28, 2017; DOI: https://doi.org/10.5535/arm.2017.41.6.1088

Abstract
PDF

Neuropathic pain is usually managed pharmacologically, rather than with botulinum toxin type A (BTX-A). However, medications commonly fail to relieve pain effectively or have intolerable side effects. We present the case of a 62-year-old man diagnosed with an intracranial chondrosarcoma, which was removed surgically and treated with radiation therapy. He suffered from neuropathic pain despite combined pharmacological therapy with gabapentin, amitriptyline, tramadol, diazepam, and duloxetine because of adverse effects. BTX-A (100 units) was injected subcutaneously in the most painful area in the posterior left thigh. Immediately after the injection, his pain decreased significantly from 6/10 to 2/10 on a visual analogue scale. Pain relief lasted for 12 weeks. This case report describes intractable neuropathic pain caused by a brain tumor that was treated with subcutaneous BTX-A, which is a useful addition for the management of neuropathic pain related to a brain tumor.

Citations

Citations to this article as recorded by

The Esthetic Use of Botulinum Toxins in Cancer Patients: Providing a Foundation for Future Indications
Marco Papagni, Monica Renga, Selene Mogavero, Paolo Veronesi, Maurizio Cavallini
Toxins.2025; 17(1): 31. CrossRef
A Systematic Review of Non-Opioid Pain Management in Chiari Malformation (Type 1) Patients: Current Evidence and Novel Therapeutic Opportunities
Awinita Barpujari, Alina Kiley, Jennifer A. Ross, Erol Veznedaroglu
Journal of Clinical Medicine.2023; 12(9): 3064. CrossRef
Botulinum Toxin Treatment for Cancer-Related Disorders: A Systematic Review
Delaram Safarpour, Bahman Jabbari
Toxins.2023; 15(12): 689. CrossRef
Botulinum Neurotoxins and Cancer—A Review of the Literature
Shivam O. Mittal, Bahman Jabbari
Toxins.2020; 12(1): 32. CrossRef
Ocular Neuropathic Pain: An Overview Focusing on Ocular Surface Pains

Nazanin Ebrahimiadib, Fardin Yousefshahi, Parisa Abdi, Mohammadreza Ghahari, Bobeck S Modjtahedi
Clinical Ophthalmology.2020; Volume 14: 2843. CrossRef